Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1

Abstract

Our findings, in addition to unlinking mechanisms of immunosuppression from that of tumor progression, suggest that rapamycin may be of value for the management of posttransplant malignancy.